Arcturus Therapeutics
Update in progressARCT (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Arcturus Therapeutics Holdings Inc. is a San Diego‑based messenger RNA medicines company focused on liver and respiratory rare diseases. Its STARR self‑amplifying mRNA platform and LUNAR lipid delivery system support programs such as ARCT-032 (LUNAR-CF) for cystic fibrosis in Phase 2, ARCT-810 (LUNAR-OTC) for OTC deficiency in Phase 2, KOSTAIVE (COVID-19 vaccine), ARCT-2138 (LUNAR-FLU) in Phase 1, and ARCT-2304 (LUNAR-H5N1) in Phase 1 for pandemic flu.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Joseph E. Payne M.Sc.
- Founded2013
- Employees106
- Websitearcturusrx.com
Identifiers
- ISINUS03969T1097
- FIGIBBG00NNW8JK1
- CUSIP03969T109
- CIK0001768224